



Company Announcement

Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer

Oslo, Norway, June 13, 2022 – Nykode Therapeutics ASA (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today the appointment of Klaus Edvardsen, M.D., Ph.D., as Chief Development Officer. The appointment will take effect on July 1, 2022.

Chief Executive Officer of Nykode Therapeutics, Michael Engsig, said: “I am very pleased to welcome Klaus to Nykode Therapeutics’ executive management team. Klaus brings tremendous international leadership experience in directing successful drug development programs at renowned biopharmaceutical companies. As Nykode’s candidates continue to advance through the clinical, we are eager for Klaus’ significant contributions to our drug development strategies.”

“I am very excited to be joining Nykode Therapeutics,” said Klaus Edvardsen, M.D., Ph.D. “Nykode has developed a unique platform technology and has entered into some impressive collaborations and partnerships with world-class biopharmaceutical companies. With its strong development pipeline, Nykode has built a great momentum on its quest to develop game changing medicines across an expanding range of therapeutic areas and I look forward to joining the team.”

Klaus Edvardsen joins Nykode from CureVac where he held a similar role as Chief Development Officer. Other previous roles include Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca, where he was responsible for the overall development strategy for oncology and hematology programs. Klaus Edvardsen also held leadership roles at both GlaxoSmithKline and Genmab in medicines development within various therapeutic areas. Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.



Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.

The Company's partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at www.nykode.com.

Contact for Nykode Therapeutics ASA:

CEO Michael Engsig
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gautstadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.